SCHEMBL2243565

SCHEMBL2243565

NC(c1ccccc1)[C@H](NS(=O)(=O)c1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
XBP1 P17861 1/20 0.47
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
MAPK1 P28482 1/20 0.45
MMP2 P08253 5/20 0.45
CA12 O43570 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15841411 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL15841410 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL2243560 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL810701 1.00 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL3862569 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1LMNANPSR1
SCHEMBL2067895 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1LMNANPSR1
SCHEMBL3852094 0.89 GBA1 (0.51) SLC1A3SLC1A2SLC1A1LMNANPSR1
SCHEMBL7089076 0.87 GBA1 (0.50) SLC1A3SLC1A2SLC1A1LMNANPSR1
SCHEMBL13191678 0.86 SLC1A3 (0.50) SLC1A3SLC1A2SLC1A1MEN1KMT2A
SCHEMBL7092770 0.85 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-09-12 US claimed
EP-1944291-B1 Optically active cyclic alcohol compound and method for producing same MITSUBISHI TANABE PHARMA CORP (JP) 2012-06-13 EP claimed
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-17 US claimed
EP-1944291-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-16 EP claimed
US-8754221-B2 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-06-17 US disclosed
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-09-12 US disclosed
EP-2371820-B1 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORP (JP) 2013-08-28 EP disclosed
US-8471028-B2 Optically active cyclic alcohol compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-25 US disclosed
EP-1944291-B1 Optically active cyclic alcohol compound and method for producing same MITSUBISHI TANABE PHARMA CORP (JP) 2012-06-13 EP disclosed
EP-2371820-A1 Optically active cyclic alcohol compound and method for preparing the same Mitsubishi Tanabe Pharma Corporation (JP) 2011-10-05 EP disclosed
US-20110196157-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION 2011-08-11 US disclosed
US-7989627-B2 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-02 US disclosed
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-17 US disclosed
EP-1944291-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196157-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME ADH1C, ADH1A, ADH5 SLC1A3 3110/4885SLC1A2 2955/4885SLC1A1 3397/4885
US-20100152451-A1 OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME ADH1C, ADH1A, ADH5 SLC1A3 3110/4885SLC1A2 2955/4885SLC1A1 3397/4885
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same ADH1C, ADH1A, ADH5 SLC1A3 3110/4885SLC1A2 2955/4885SLC1A1 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.